Lazard Asset Management
CODX

Lazard Asset Management’s Co-Diagnostics CODX Stock Holding History

Lazard Asset Management’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-670
Closed -$112K – 2350
2022
Q2 		$112K Buy
670
+337
+101% +$51.3K ﹤0.01% 1469
2022
Q1 		$61K Buy
333
+5
+2% +$1.03K ﹤0.01% 1639
2021
Q4 		$87K Buy
328
+59
+22% +$15.5K ﹤0.01% 1492
2021
Q3 		$78K Buy
+269
New +$78.5K ﹤0.01% 1490

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Lazard Asset Management's CODX Position: Q3 2022 in Review

Lazard Asset Management sold out of Co-Diagnostics (CODX) in Q3 2022, closing a stake of 670 shares — an estimated $112K sold.

Lazard Asset Management first reported a position in CODX in Q3 2021 and held it in 4 quarters. The position peaked at $112K in Q2 2022. 65 funds tracked by Wall St. Rank hold CODX as of Q3 2022.

  • Lazard Asset Management reported no remaining Co-Diagnostics position as of Q3 2022 after selling out during the quarter.
  • Lazard Asset Management sold 670 Co-Diagnostics shares in Q3 2022, an estimated $112K.
  • Lazard Asset Management first reported a position in Co-Diagnostics in Q3 2021 and held it in 4 quarters.
  • Lazard Asset Management's Co-Diagnostics position peaked at $112K in Q2 2022.
  • 65 funds tracked by Wall St. Rank held Co-Diagnostics as of Q3 2022.

Based on Lazard Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.